36 results about "Thyrotropin receptor" patented technology

A method of detecting thyroid cancer in a subject includes obtaining a nucleic acid sample from a bodily sample of the subject and determining whether the nucleic acid sample contains at least one of thyroid stimulating hormone receptor (TSHR) mRNA or thyroglobulin (Tg) mRNA.

A binding partner for the TSH receptor, which binding partner comprises, or is derived from, a human monoclonal or recombinant antibody, or one or more fragments thereof, reactive with the TSH receptor, uses thereof, methods of diagnosis and therapy employing the same, and anti-idiotypic antibodies thereto.

This invention describes monoclonal antibodies that suppress thyrotropin receptor constitutive activity and methods of using the antibodies to treat thyroid related diseases; particularly hyperthyroidism and thyroid cancer

The invention relates to the technical field of in-vitro diagnosis, in particular to a kit for detecting the concentration of a stimulating thyrotrophin receptor antibody. The kit comprises magnetic particles coated with a stimulating thyrotrophin receptor antibody, a stimulating thyrotrophin receptor containing a marker label, and a stimulating thyrotrophin receptor antibody calibration product.According to the invention, the stimulating thyrotrophin receptor is used for constructing a stimulating thyrotrophin receptor antibody kit for the first time and the stimulating thyrotrophin receptoris only bound with the stimulating thyrotrophin receptor antibody, thereby eliminating the influence on the measuring system by the inhibiting thyrotrophin receptor antibody and the neutral thyrotrophin receptor antibody. The construction of the kit detection method is based on the high-sensitivity chemiluminiscence determination technology and the high-specificity immune reaction is combined; and thus the method has advantages of high sensitivity, high specificity and wide detection range.

The invention discloses the expressing product of human thyrotropin receptor extracellular domain amino terminus gene and its preparation methods and the application of the product in the enzyme immunoassay technology. The purpose of this invention is to divide TSHR-ecd cDNA into three regions(hTSHR-N terminal, hTSHR-C terminal and hTSHR-M terminal), clone them respectively, especially the hTSHR-N terminal, construct expression vector, express in E.coli, and establish TRAb (including TSAb. TSBAb) ELISA technology taking the protein of this gene engineering fragmentas antigen. The said invention develops novel channel for further research of TSHR antigen determinant and settles foundation for the ultimate transformation into TSAb, TSBAb clinical diagnostic kit.

The invention relates to a human thyrotropin receptor antibody chemiluminescence detection kit as well as a preparation method and an application method thereof, and belongs to the technical field ofimmunoassay medical detection. The method can be used for solving the problems that an existing immunoassay method for detecting the human thyrotropin receptor antibody cannot distinguish stimulating,inhibition and neutralizing antibodies of human thyrotropin receptors, and the detection sensitivity and accuracy are poor. The kit disclosed by the invention uses a streptavidin-biotin system at thecombinational ratio of streptavidin to biotin of 1:4, so that the signal is further amplified, and the reagent sensitivity is improved. Specificity detection of the stimulating antibodies of the thyrotropin receptor is carried out by changing the marked antibody and the antigen, so that detection specificity is enhanced and more accurate and more targeted in-vitro diagnosis reagents are providedfor clinical diagnosis. The kit adopts a one-step competition method reaction mode, and the content of the stimulating antibodies of the thyrotropin receptor in human serum is quantitatively detected,so that the sensitivity and specificity of detection are ensured.

The invention discloses the expressing product of human thyrotropin receptor extracellular domain carboxy-terminal gene and its preparation methods and the application of the product in the enzyme immunoassay technology. The purpose of this invention is to divide TSHR-ecd cDNA into three regions(hTSHR-N terminal, hTSHR-C terminal and hTSHR-M terminal), clone them respectively, especially the hTSHR-C terminal, construct expression vector, express in E.coli, and establish TRAb (including TSAb. TSBAb) ELISA technology taking the protein of this gene engineering fragmentas antigen. The said invention develops novel channel for further research of TSHR antigen determinant and settles foundation for the ultimate transformation into TSAb, TSBAb clinical diagnostic kit.

The invention provides an isolated antibody for the TSHR which is an antagonist of TSH. The invention also relates to methods of using antibodies of the invention.

The invention relates to a bridge assay that can be used on an automatic diagnostic apparatus in order to detect anti-thyrotropin receptor autoantibodies, wherein the chimeric TSH receptor used comprises the extracellular portion of the chimeric TSH receptor and is N-terminally fused to a protein causing secretion of the chimeric TSH receptor from culture cells, and the anchored chimeric TSH receptor is immobilized on paramagnetic particles.

The present invention provides a peptide at least partially derivable from human Thyroid Stimulating Hormone Receptor (TSHR) which peptide is capable of binding to an MHC molecule in vitro and being presented to a T cell without further antigen processing. The present invention also relates to the use of such peptides for the prevention or suppression of activating autoantibody formation in Graves' Disease.

The invention discloses an enzyme-linked immunoassay kit and a detection method capable of simultaneously detecting thyroid stimulating hormone receptor subtype antibodies. The kit comprises a coatingantigen, a precoated ELISA plate, a rinsing solution, a thyroid stimulating hormone receptor antibody standard, an ELISA solution, a diluted sample solution, a rinsing solution, a blocking solution,a color developing solution and a stop solution. The detection method comprises the following steps: coating, washing, adding a sample, washing, developing the color and stopping. The kit is high in sensitivity, good in specificity and easy to operate, and can be used for quantitatively detecting the concentrations of the thyroid stimulating hormone receptor subtype antibodies; a result obtained after detection through use of the kit and the detection method has an important clinical reference value; the kit is low in price, is convenient for clinical wide-range popularization, and provides aprecise reference for a clinician to diagnose diseases.

The invention provides an isolated antibody for the TSHR which is an antagonist of TSH. The invention also relates to methods of using antibodies of the invention.

Improved receptor assays for the detection of thyroid stimulating hormone receptor (TSHR) autoantibodies are described which use immobilized, affinity-purified rTSHR preparations as specific binders. This format, as well as novel measures for neutralizing pathologically increased human TSH (hTSH) levels in the sera, e.g., by the addition of anti-hHSH antibody, and / or eliminating the influence of anti-bovine TSH antibody, result in increased assay reliability and open up the possibility of preparing the assay constituents in a ready to use and / or well-standardized form for automatic processing and / or convenient marketing.

The invention provides a kit for detecting TSHR (thyroid stimulating hormone receptor) gene mRNA expression through a fluorescence quantitation RT-PCR (real-time polymerase chain reaction) and a use method of the kit. The kit detects the existence of expression of TSHR-mRNA in peripheral blood, tumor tissue samples and the like and the expression level with a Taqman-qPCR method. The kit has the advantages of high sensitivity, high accuracy, high detection rate and specificity, is matched with an internal standard and a positive reference substance, can effectively eliminate false positive and false negative results, is high in anti-jamming capacity and has the characteristics that detection is quick and economical, trauma of patients is small and the product stability is high.

The present invention provides a peptide at least partially derivable from human Thyroid Stimulating Hormone Receptor (TSHR) which peptide is capable of binding to an MHC molecule in vitro and being presented to a T cell without further antigen processing. The present invention also relates to the use of such peptides for the prevention or suppression of activating autoantibody formation in Graves' Disease.

The invention relates to the technical field of biology, in particular to a human thyroid stimulating hormone receptor fusion protein and a preparation method and application thereof. The fusion protein is composed of a HER2 protein and a TSHR protein, and the HER2 protein and the TSHR protein are connected through a connecting peptide. The HER2 and the low-expression TSHR are subjected to fusionexpression, the yield and stability of the TSHR can be improved under the condition that the structure and function of the TSHR are not affected, the TSHR protein can be secreted into supernate, and purification is facilitated.

Disclosed are a fusion protein comprising a thyrotropin receptor (TSHR) fragment and the use thereof. More specifically, disclosed are a fusion protein comprising a TSHR fragment comprising an extracellular domain of a wild-type TSHR and having a substitution of an amino acid at specific position and an immunoglobulin Fc region or a carboxy-terminal cap (C-CAP), and the use thereof. The fusion protein has improved pharmaceutical efficacy, in-vivo persistence and protein stability and a pharmaceutical composition containing the fusion protein as an active ingredient is useful as a therapeutic agent or diagnostic reagent for the alleviation of Graves' disease and Graves' ophthalmopathy.

TSHR agonists that are substantially desialylated are described for treating metabolic syndrome and obesity and for inducing lipolysis. The TSHR polypeptide agonists are useful for treatment of hallmarks of metabolic syndrome: obesity, insulin resistance, hyperlipidemia, and liver steatosis, without producing a hyperthyroid state in treated individuals.

Dual suppression of the MAP kinase and PI3K / Akt pathways showed synergistic or greatly enhanced anti-melanoma cell effects, compared to suppression of a single pathway, including the inhibition of cell proliferation, transformation and invasion, induction of G0 / G1 cell cycle arrest and, importantly, cell apoptosis. Remarkably, suppression of either pathway induces the expression of thyroid iodide-handling genes and dual suppression of the two pathways synergistically and robustly induces expression of these genes, accompanied by uptake of radioiodine in the cells. These genes include sodium / iodide symporter, thyroid-stimulating hormone receptor, thyroglobulin, thyroperoxidase, pendrin gene, thyroid transcription factors (e.g., TTF-1, TTF-2, PAX8) and other thyroid genes. Targeting major signaling pathways, such as the MAP kinase and PI3K / Akt pathways, for potent cell death, optionally coupled with induction of thyroid gene expression for adjunct radioiodine ablation therapy may be used for many human cancers, both thyroid and non-thyroid.

The invention discloses a construction method of a gene immune induced Graves' Ophthalmopathy animal model and application of a rapamycin type medicine. The construction method comprises the followingsteps: 1) diluting a mother liquid of an adenovirus expressing a thyroid-stimulating hormone receptor by using PBS (phosphate buffer saline) according to a volume ratio of 1:50 so as to obtain an Ad-TSHR (adenovirus-thyroid-stimulating hormone receptor) diluted liquid; 2) on the first day of a first week, respectively injecting 25[mu] L of the Ad-TSHR diluted liquid into left gluteus maximus muscle and right gluteus maximus muscle of experiment animals; and 3) repeating operation of the step 2) at the 3rd, 10th, 14th, 18th, 22nd, 26th and 30th weeks till the experiment animals are induced tohave Graves' Ophthalmopathy, so as to successfully construct the gene immune induced Graves' Ophthalmopathy animal model. The construction method makes up the blank of the field of Graves' Ophthalmopathy models, and is a novel exploration on rapamycin in treating Graves' Ophthalmopathy.